2C-I

The existing subsection is supported but materially underspecified. Austria's current consolidated SV expressly lists 2C-I in Anhang V.2 and extends that row to the stated isomer, ester, ether, molecular-compound, salt and preparation clauses. Under SMG § 5, Suchtmittel may be handled only for medical, dental, veterinary or scientific purposes and under the Act; unauthorized acquisition, possession, production, transport, import/export, offering, transfer or supply is criminalized by SMG § 27, with personal-use and other fact-specific qualifications. This supports the canonical status prohibited for ordinary non-authorized conduct, not an absolute claim that every act is unlawful. SV § 14 also bars prescribing preparations made from Anhang V substances (subject to cannabis-specific exceptions that do not apply to 2C-I), so no ordinary prescription route is established. The SGV 12.0 g figure is a criminal Grenzmenge calculated as pure active substance/free base, not a lawful possession allowance. The Austrian schedule gives the trivial name 2C-I; UNODC corroborates the chemical identity as 2,5-dimethoxy-4-iodophenethylamine. This packet does not decide analytical identity of a sample, purity, salt/base calculation in a particular case, authorization, import facts, or prosecutorial outcome.

Supported current primary-source result for mainland China's national controls. The official Shenzhen Public Security Bureau current directory expressly places 2C-I in section III, the non-medical narcotic and psychotropic directory, as entry 241. Under Article 4 of the current national regulation, non-medical listed substances may be used only for legally compliant experimental research and may not be produced, dealt in, used, stored, or transported; this is a prohibited status, not ordinary prescription-only access. The 2025 medicinal schedules are separate from the non-medical directory. The result concerns the exact listed 2C-I identity (CAS 69587-11-7); derivatives or analogues require separate identity analysis. The official Ministry of Public Security attachment linked by the Xinjiang police portal returned HTTP 521 in this pass, so the current official Shenzhen police portal and the official police announcement reproduction were used. This is limited to mainland China's national directories and the law available on 2026-08-27.

The current 2026 regulation supersedes the stale 2020 instrument and identifies 2C-I precisely as List B item 97. List B substances may only be used for medical and scientific purposes, and the handling rule leaves no ordinary private-use or possession exception. The regulation's permissions are limited to specified medical/scientific actors, prescriptions or requisitions, agency-authorized activities and import/export certificates; its List A no. 2 treatment carve-outs and state-laboratory manufacture exception are narrow and do not make 2C-I generally lawful. Status normalized to prohibited.

The existing entry is substantively supported but should identify the instrument as the 11 January 2005 Ministry decree rather than a generic statement. The decree expressly names 2C-I as 2,5-dimetossi-4-iodofenetilamina and adds it to Table I; it was published on 7 March 2005 and entered into force the following day. A later official Table I schedule snapshot (2020) still prints both the common name 2C-I and the Italian chemical designation. Italy's current Normattiva page reports the consolidated D.P.R. 309/1990 view as vigente al 27/08/2026 and updated 06/08/2026. This supports canonical prohibited as a Table I scheduling classification, not a prescription-only classification. The packet does not make a fact-specific determination about personal-use administrative treatment, research authorization, or every possible product/form exception.

Supported and corrected in precision. The existing entry's Schedule 3/Class C analogue conclusion is substantively correct, but the controlling rule is the specific Schedule 3 Part 7 amphetamine-analogue description rather than an unspecified catch-all. UNODC identifies 2C-I as 4-iodo-2,5-dimethoxyphenethylamine (IUPAC: 2-(4-iodo-2,5-dimethoxyphenyl)ethan-1-amine). The current New Zealand Act expressly defines Class C to include controlled drug analogues and defines an analogue by substantial structural similarity; Part 7's 1-amino-2-phenylethane rule reaches this identity. The Act's current named schedules separately list DOB, DMA, DMT and other substances, and Schedule 2 separately lists 25I-NBOMe (the N-(2-methoxybenzyl) derivative); neither should be conflated with parent 2C-I. Sections 6 and 7 retain criminal prohibitions on unauthorised controlled-drug import/export, production/manufacture, possession, consumption/use, and specified supply/sale. This is an analogue-covered Class C result, not an exact-name listing, prescription classification, or claim that 25I-NBOMe's Class B status applies to parent 2C-I. The New Zealand Legislation page was rendered in an interactive browser after its AWS WAF challenge; the direct read backend returned the challenge, but the official page displayed the current consolidated text and version date. The separate New Zealand dossier supplied for this wave is alpha-PVP-specific and was not used to transfer that substance's Class A status to 2C-I.

Supported current-law correction. The existing entry's substance identity is confirmed, but its instrument name and status wording should be updated: the current ordinance is BetmVV-EDI (not the former DetMV name), and Verzeichnis d is the prohibited controlled-substance category. The current consolidated schedule expressly lists 2,5-Dimethoxy-4-iodo-phenethylamin (2C-I) in Annex 5 Verzeichnis d. BetmG Article 19(1)(d) makes unauthorized possession, custody, acquisition or other acquisition of narcotics punishable by up to three years' imprisonment or a fine. The schedule and statute support prohibited/unauthorized possession, not an absolute statement that every possible possession is unlawful: licensed handling and BAG exceptions remain governed by the authorization framework. The prior 12 December 1996 historical-date assertion was not needed for the current classification and was not independently relied upon; the inspected current sources do not establish that date.

The prior uncited note is directionally correct but incomplete. Belgium expressly added 2C-I (2,5-dimethoxy-4-iodophenethylamine) to the former psychotropic list in the Royal Decree published on 8 November 2004, effective 18 November 2004. That 1998 psychotropic decree was later repealed by the 2017 controlled-substances decree. The current AFMPS working consolidation, valid from 29 March 2026 and corrected 16 July 2026, places 2C-X derivatives in Annex IVa under a generic structure; its 2C-X parent is 2-(2,5-dimethoxyphenyl)ethanamine and the listed R4 substituents include halogen, so the 4-iodo compound 2C-I is covered. Under current Article 7, importing, exporting, transporting, manufacturing, possessing, selling, supplying, delivering or acquiring scheduled products requires prior authorization, with authorization limited to scientific or medical purposes; this supports prohibited rather than legal_regulated, unscheduled or decriminalized. The AFMPS schedule PDF is expressly a non-official consolidation: only Annexes and amendments published in the Moniteur belge have official legal value. Accordingly, the exact current generic-schedule application is strongly evidenced by the regulator's current working copy and the 2004 official publication, but a litigation-grade determination should cross-check the authoritative Moniteur belge annex image for the current amendment. No ordinary recreational or personal-use exception was found in the inspected official sources.

The current e-Sbírka rendition inspected on 27 August 2026 identifies itself as current from 25 June 2026 and directly lists Ioddimethoxyfenethylamin, 2C-I and its chemical identity in Annex 4, List 4. This supports the legacy entry's controlled classification but does not establish the legacy note's assertion that the substance was added in early 2011; that historical date is not carried forward. The canonical prohibited label means unauthorized handling under the addictive-substance schedule, not an absolute ban on every licensed scientific or very limited therapeutic activity. The cited texts do not enumerate individual permit holders, enforcement outcomes, or medicinal-product authorizations.

The legacy row is substantively supported and should be normalized from the non-canonical status Controlled to prohibited. The current ANSM consolidation places 2-CI in Annexe IV and attributes the entry to the 18 August 2004 amendment. This is an explicit named entry, not an inference from a generic analogue rule; it is also distinct from the separately listed 25I-NBOMe/2C-I-NBOMe entry. The ANSM PDF is an indicative compilation: it states that only the amended 22 February 1990 ministerial order and published ANSM director-general decisions are legally opposable, and that the Legifrance version does not include ANSM decisions since February 2022. The Ministry's PEPPS reference describes the general prohibition and offense-level penalties for classified narcotics. No prescription-medicine route is asserted for raw 2-CI; the inspected material does not establish an authorized medicinal presentation.

The exact parent compound is expressly listed in Greece's Table A at entry 43 of the official Law 3459/2006 Gazette. Under Law 4139/2013, Table A production, possession, transport, storage, procurement, processing, circulation and intermediation are State-exclusive, and disposal is limited to laboratories or hospitals for approved programs. This supports the normalized disposition prohibited rather than prescription_only or OTC. The Ministry of Health's current consolidated-table page was also checked but returned HTTP 503; therefore the packet does not claim that every intervening amendment was exhaustively machine-read. The latest located official Gazette amendment (11 June 2026) adds 2-MMC, NEP and 4-BMC to Table A and does not itself address 2C-I. No medicine authorization or lawful consumer channel is asserted.

The legacy Controlled classification is supported but normalized to the statutory category dangerous drug and canonicalStatus prohibited. The exact 2C-I identity is directly listed in First Schedule item 9A. Sections 7 and 13 make unauthorized possession/use and import/export/trade/other dealing/supply unlawful, while sections 7(c) and 19A state statutory maximums; these are maximum penalties, not automatic sentences, and licensing/statutory exceptions remain relevant. The current Ministry of Health import guidance requires the applicable permit/licence sequence, and the current Digital Personal Import Order places dangerous drugs in regulated First Schedule tariff categories under the Pharmacy Division. The latest official schedule amendment located is dated 8 June 2025; no separate 2026 First Schedule amendment was located in the inspected official searches. The consolidated legal text available through the Ministry-linked legal database states it is current as of 17 June 2025, so claims are bounded to that latest consolidated text and the later 2025 Gazette/current 2026 import guidance rather than asserting an unseen later amendment.

The original designated-substance classification and Pharmaceutical Affairs/PMD Act basis are superseded. MHLW's current list identifies 2C-I among substances formerly controlled as designated substances and records the 18 January 2008 reclassification; the current e-Gov Cabinet Order expressly lists the corresponding chemical identity and salts as a narcotic. Accordingly, the ordinary rule is prohibited under the Narcotics and Psychotropics Control Act, while the Act preserves licensed, research, disease-treatment/prescription, specified transfer, and permission-based treatment-import pathways. Those statutory pathways are not evidence that unlicensed recreational possession, sale or transfer is permitted, and the record does not assert that 2C-I is an approved medicine.

The current consolidated Läkemedelsverket schedule expressly identifies the exact parent compound 2C-I as 4-jodo-2,5-dimetoxifenetylamin and places it in Swedish list I. List I is defined by the schedule as substances normally without medical use. Under the current Narcotic Drugs Act, narcotics may be imported, exported, manufactured, offered for sale, transferred or possessed only for specified medical, scientific, specially important public-interest or permitted industrial purposes, and possession is limited to enumerated authorized categories; ordinary recreational possession, sale and supply are therefore prohibited. The live entry's underlying Schedule I conclusion is supported, but its historical attribution to Sveriges riksdag should be replaced with the current Läkemedelsverket schedule and statutory framework. This is primary-source legal-information research, not an individualized legal opinion.

Supported replacement. The official EGM/TUBİM 2013 national report's Annex 1 is expressly a list of substances brought within the scope of Law No. 2313 by Council of Ministers decisions and names 2C-I as 2,5-Dimethoxy-4-iodophenethylamine in the phenethylamine group under the 22 May 2013 Decision No. 2013/4827. The official EGM/Narkotik 2025 report confirms that Law No. 2313 remains one of Turkey's three fundamental drug-control statutes and that the TCK criminalizes manufacture/trade/supply and purchase, possession or use of narcotic/stimulant substances. The 2025 report does not reproduce the individual 2C-I entry, so the substance-specific identification relies on the official 2013 annex reproduction; direct Resmî Gazete and consolidated mevzuat.gov.tr endpoints were not inspectable in this run because of certificate failures.